for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Prothena Corporation PLC

PRTA.O

Latest Trade

39.53USD

Change

2.29(+6.15%)

Volume

649,606

Today's Range

35.78

 - 

39.80

52 Week Range

10.72

 - 

79.75

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
37.24
Open
36.71
Volume
649,606
3M AVG Volume
8.55
Today's High
39.80
Today's Low
35.78
52 Week High
79.75
52 Week Low
10.72
Shares Out (MIL)
46.59
Market Cap (MIL)
1,841.85
Forward P/E
27.04
Dividend (Yield %)
--

Next Event

Q4 2021 Prothena Corporation PLC Earnings Release

Latest Developments

More

Prothena Corp PLC Says Brandon Smith Has Been Appointed Chief Operating Officer

Prothena Reports Second Quarter 2021 Financial Results

Prothena And Novo Nordisk Announce Acquisition Agreement For Prothena’S Attr Amyloidosis Programme

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Prothena Corporation PLC

Prothena Corporation PLC is a late-stage clinical company. The Company is engaged in the protein dysregulation and a pipeline of therapeutics for devastating neurodegenerative and rare peripheral amyloid diseases. It is advancing a pipeline of therapeutic candidates around neurological dysfunction and the biology of misfolded proteins. The Company's clinical pipeline of antibody-based product candidates targets a range of indications, including Birtamimab for the treatment of amyloid light-chain (AL) amyloidosis; prasinezumab for the treatment of Parkinson’s disease and other related synucleinopathies; and PRX004, for the treatment of Transthyretin amyloidosis (ATTR). The Company's pipeline also includes late-preclinical-stage programs targeting proteins implicated in neurological diseases including tau and amyloid beta (Aβ) for the treatment of Alzheimer’s disease and other neurodegenerative disorders, and TDP-43 for the treatment of amyotrophic lateral sclerosis.

Industry

Biotechnology & Drugs

Contact Info

77 Sir John Rogersons Quay

Block C, Grand Canal Docklands

D02 T804

Ireland

+353.1.2362500

http://www.prothena.com/

Executive Leadership

Lars G. Ekman

Independent Chairman of the Board

Gene G. Kinney

President, Chief Executive Officer, Director

Tran B. Nguyen

Chief Financial Officer, Chief Strategy Officer

Brandon S. Smith

Chief Operating Officer, Chief Business Officer

Karin L. Walker

Chief Accounting Officer, Controller

Key Stats

1.67 mean rating - 9 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

0.0K

2019

0.0K

2020

0.0K

2021(E)

0.2K
EPS (USD)

2018

-3.930

2019

-1.950

2020

-2.780

2021(E)

1.462
Price To Earnings (TTM)
38.21
Price To Sales (TTM)
9.22
Price To Book (MRQ)
3.75
Price To Cash Flow (TTM)
26.05
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
14.81
Return on Equity (TTM)
14.05

Latest News

Latest News

Novo Nordisk to buy Prothena's heart drug in deal worth up to $1.2 billion

Danish drugmaker Novo Nordisk will acquire U.S. drug developer Prothena Corp's experimental heart therapy, PRX004, in a deal that could be worth up to $1.23 billion, the companies said on Monday.

U.S. RESEARCH ROUNDUP-Ashland Global, Lyft, Solaredge Technologies

Wall Street securities analysts on Thursday revised their ratings and price targets on several U.S.-listed companies, including Ashland Global Holdings, Lyft and Solaredge Technologies. HIGHLIGHTS * Ashland Global Holdings Inc. : JP Morgan raises to neutral from underweight...

BRIEF-Prothena Corporation Plc- Update On Prasinezumab Expected Later This Year

* UPDATE ON PHASE 2 PASADENA STUDY OF PRASINEZUMAB (PRX002/RG7935) IN PARKINSON’S DISEASE

BRIEF-Baseline Data From Phase 2 Pasadena Study Of Prasinezumab In Parkinson's Disease To Be Presented At AAT-AD/PD

* BASELINE DATA FROM PHASE 2 PASADENA STUDY OF PRASINEZUMAB (PRX002/RG7935) IN PARKINSON’S DISEASE TO BE PRESENTED AT AAT-AD/PD Source text for Eikon: Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up